4.7 Article

Design of nucleotide-mimetic and non-nucleotide inhibitors of the translation initiation factor eIF4E: Synthesis, structural and functional characterisation

期刊

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 124, 期 -, 页码 200-217

出版社

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2016.08.047

关键词

Cancer; eIF4E; Protein synthesis; mRNA translation; Cap-binding inhibitor

资金

  1. Association for International Cancer Research (AICR) [06-063]
  2. Medical Research Council (MRC)
  3. Cancer Research UK (CRUK) [C18648/A10174]
  4. Wellcome Trust [081287/Z/06/Z, 101527/Z/13/Z]
  5. University of Damascus, Syria
  6. Wellcome Trust [081287/Z/06/Z] Funding Source: Wellcome Trust
  7. Biotechnology and Biological Sciences Research Council [BB/H024980/1, BB/F02326X/2] Funding Source: researchfish
  8. BBSRC [BB/H024980/1, BB/F02326X/2] Funding Source: UKRI

向作者/读者索取更多资源

Eukaryotic translation initiation factor 4E (eIF4E) is considered as the corner stone in the cap-dependent translation initiation machinery. Its role is to recruit mRNA to the ribosome through recognition of the 5'-terminal mRNA cap structure (m(7)GpppN, where G is guanosine, N is any nucleotide). eIF4E is implicated in cell transformation, tumourigenesis, and angiogenesis by facilitating translation of oncogenic mRNAs; it is thus regarded as an attractive anticancer drug target. We have used two approaches to design cap binding inhibitors of eIF4E by modifying the N-7-substituent of m(7)GMP and replacing the phosphate group with isosteres such as squaramides, sulfonamides, and tetrazoles, as well as by structure-based virtual screening aimed at identifying non-nucleotide cap-binding antagonists. Phosphomimetic nucleotide derivatives and highly ranking virtual hits were evaluated in a series of in vitro and cell-based assays to identify the first non-nucleotide eIF4E cap-binding inhibitor with activities in cell-based assays, N-[(5,6-dihydro-6-oxo-1,3-dioxolo[4,5-g]quinolin-7-yl)methyli-N'-(2-methyl-propy1)-N-(phenylmethypthiourea (14), including down-regulation of oncogenic proteins and suppression of RNA incorporation into polysomes. Although we did not observe cellular activity with any of our modified m(7)GMP phosphate isostere compounds, we obtained X-ray crystallography structures of three such compounds in complex with eIF4E, 5'-deoxy-5'-(1,2-dioxo-3-hydroxycyclobut-3-en-4-yl)amino-N-7-methyl-guanosine (4a), N-7-3-chlorobenzy1-5'-deoxy-5'-(1,2-dioxo-3-hydroxy-cyclobut-3-en-4-yl)amino-guanosine (4f), and N-7-benzyl-5'-deoxy-5'-(trifluoromethyl-sulfamoyl)guanosine (7a). Collectively, the data we present on structure-based design of eIF4E cap-binding inhibitors should facilitate the optimisation of such compounds as potential anticancer agents. (C) 2016 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY license.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据